Keratin 17 as a biomarker for bladder cancer
AssigneesThe Research Foundation for The State University of New York, Kdx Diagnostics, Inc.
InventorsKenneth R. Shroyer, Luisa F. Escobar-Hoyos, Nam Kim
Life of this patent
Estimating the term…
Abstract
The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.
Claims10
A method of diagnosing bladder cancer in a subject comprising:
- obtaining a urine sample from a subject, wherein said sample comprises a plurality of bladder cells;
- detecting K17 expression in said bladder cells of said sample, wherein said detection comprises contacting said urine sample with an anti-K17 antibody, and detecting binding between K17 on said bladder cells and the anti-K17 antibody;
- obtaining a control urine sample comprising a plurality of bladder cells, wherein the control urine sample is a sample of urine from an individual free of bladder cancer;
- detecting K17 expression in said bladder cells of the control urine sample, wherein said detection comprises contacting the control urine sample with the anti-K17 antibody, and detecting binding between K17 on said bladder cells in the control urine sample and the anti-K17 antibody;
- diagnosing the subject with bladder cancer when between a 10-fold and a 60-fold increase in the amount of K17 expression is detected in the plurality of bladder cells of the subject when compared to the amount of K17 expression detected in the plurality of bladder cells of the control urine sample;
- and
- administering a treatment modality configured for the bladder cancer to the subject when between the 10-fold and the 60-fold increase in the amount of K17 expression is detected in the plurality of bladder cancer cells.
A method for diagnosing a subject with bladder cancer comprising:
- obtaining a urine sample from a subject, wherein said urine sample comprises a plurality of bladder cells;
- detecting keratin 17 (K17) protein expression in said bladder cells of said urine sample from the subject, wherein said detection comprises:
- contacting said bladder cells with an anti-K17 antibody, and
- detecting binding between the K17 protein on said bladder cells in the urine sample and the anti-K17 antibody by immunohistochemical analysis or enzyme-linked immunosorbent assay (ELISA);
- obtaining a control urine sample comprising a plurality of bladder cells, wherein the control urine sample is a sample of urine from an individual free of bladder cancer;
- detecting K17 protein expression in said bladder cells of the control urine sample, wherein said detection comprises:
- contacting the bladder cells in the control urine sample with the anti-K17 antibody, and detecting binding between the K17 protein on said bladder cells in the control urine sample and the anti-K17 antibody by immunohistochemical analysis or ELISA;
- and
- diagnosing the subject with bladder cancer when between a 10-fold and a 60-fold increase in the amount of K17 expression is detected in the plurality of bladder cells of the subject when compared to the amount of K17 expression detected in the plurality of bladder cells of the control urine sample;
- and
- administering a treatment modality configured for the bladder cancer to the subject when between the 10-fold and the 60-fold increase in the amount of K17 expression is detected in the plurality of bladder cancer cells.
Dependencies are inferred from the claim text.